Small cell lung cancer (SCLC) is traditionally classified into limited-stage SCLC (LS-SCLC) and extensive-stage SCLC according to whether disease is confined to one hemithorax or not. Approximately 10% of patients present with stage II and 4% with stage I SCLC under the American Joint Committee on Cancer staging system. Surgery remains a leading approach for patients with node-negative SCLC, among whom long-term survival was in the 50% range in retrospective series, exceeding expected results for a broader population with LS-SCLC.
Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer
Leggi l'articolo originale